Shaping the future of animal health
Virbac group

A company dedicated
to animal health

Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Ranked 8th worldwide and present in more than 100 countries, the company offers a comprehensive range of products and services intended for veterinarians, farmers and animal owners.

Corporate news

Dec 15 - Development of new monoclonal antibody-based veterinary medicines: Virbac announces the signature of a collaboration agreement with Nexvet

As the world's 5th largest manufacturer in the companion animal market, a major part of Virbac's Research & Development investment is made in this field. In this context, the Group is pleased to announce the signature of a ten-year collaboration agreement with biopharmaceutical company Nexvet. The aim of this agreement is for Virbac to provide input to Nexvet’s development of new monoclonal antibody-based veterinary medicines and to market these medicines, if approved by regulators, outside the USA and Canada.  

Dec 01 - Companion animals in Russia: a new start

April 2014, Moscow. At Russia's largest veterinary congress, Virbac launched Cortavance, a corticoid for the treatment of inflammatory dermatosis in dogs. A major step forward for the companion animal portfolio in this country. Explanations by the Rest of Europe product manager.

Nov 18 - Virbac Mexico: Virbac increases its global production capacity with its new site

Pierre Catignol has been appointed as its new Industrial Operations director.

Join Virbac

Career opportunities, company values, testimonials... Discover our career section.

Customer driven innovation

To meet the customers' essential needs, in almost all the therapeutic segments and for nearly all species. Such is the philosophy of Virbac innovation. For this purpose, the company develops...

Financial public releases

Oct 27 - Virbac agrees to acquire veterinary assets from Eli Lilly in the United States

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Oct 16 - 2014 third quarter consolidated sales

Confirmation of the rebound of growth in the third quarter

Aug 29 - 2014 half year results

Half-year results impacted by foreign exchange and the low level of activity in the United States

Corporate responsibility

Company culture, economic and social responsibility, citizenship, environment... From its very beginning, forty years ago, Virbac has taken a long-term view.